Research programme: macrocyclic compounds - Cyclenium Pharma

Drug Profile

Research programme: macrocyclic compounds - Cyclenium Pharma

Alternative Names: Cancer therapeutics - Cyclenium/Southern Research Institute; Cancer therapeutics - Cyclenium/University of Montreal; Gastrointestinal and metabolic disorders therapeutics - Cyclenium; Immunological disorder therapeutics - Cyclenium/University of Montreal; Infectious diseases therapeutics - Cyclenium/Fundación MEDINA; Infectious diseases therapeutics - Cyclenium/Southern Research Institute; Inflammation and pain therapeutics - Cyclenium; Neurological disorder therapeutics - Cyclenium/Southern Research Institute

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Cyclenium Pharma
  • Developer Cyclenium Pharma; Fundacion MEDINA; SickKids; Southern Research Institute; University of Montreal
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders; Metabolic disorders

Highest Development Phases

  • Research Cancer; Cardiovascular disorders; Immunological disorders; Infections; Neurological disorders

Most Recent Events

  • 07 Mar 2017 Early research in Cardiovascular disorders in USA (unspecified route)
  • 07 Mar 2017 Cyclenium Pharma and SickKids agree to co-develop macrocyclic compounds for indications immunological disorders, cardiovascular disorders and cancer
  • 11 Jun 2015 Cyclenium Pharma and McGill University agree to co-develop macrocyclic compounds in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top